Some studies performed on rat models indicate beneficial effects of ghrelin agonists on the non-motor symptoms of PD [96], while in vitro studies indicate that they may antagonize the neurotoxin activity of 1-methyl-4-phenylpyridinium (MPP+) [97]. This evidence concerns the gene GHRL and Parkinson disease.